More recently, a study in breast cancer patients showed that metformin reduces the levels of mitochondrial metabolites and increases 18-FDG flux in primary breast cancers, without apparent activation of AMPK, arguing against the involvement of this kinase in mediating the effects of metformin in this clinical context [179]. The gene discussed is PRKAA1; the disease is breast cancer.